Truly individualized treatment for every round of therapy

Aummune is a pre-clinical stage personalized cancer therapeutics company. Aummune’s proprietary technology involves a transformational molecular and computational process that relies on the patient’s tumor biopsy to generate a “customized” multi-target tumor killing agent. The method yields a DNA-based therapeutic, organized into unique 3D structure demonstrating specific tissue binding and killing with near-zero off-target effects. Aummune has completed development of a robust, reproducible therapeutic development process and demonstrated successful proof-of-concept results in hard-to-treat solid tumors. A strong patent portfolio has been established, and the company is planning to initiate its clinical program in the near term.

Leadership:

Investing partner / fund: